Successful management of pregnancy and hepatic toxicity in a CML female patient treated with nilotinib : a case report and a review
We report a case of a young patient with HBV hepatopathy, diagnosed with CML in March 2006 and treated with imatinib 400mg/die as first line therapy with concomitant Lamivudine. Patient obtained a complete hematologic response (CHR) in 2 months, complete cytogenetic response (CCyR) in six months and...
        Saved in:
      
    
          | Main Authors: | Domenico Santorsola, Elisabetta Abruzzese | 
|---|---|
| Format: | Article | 
| Language: | English | 
| Published: | PAGEPress Publications
    
        2015-02-01 | 
| Series: | Mediterranean Journal of Hematology and Infectious Diseases | 
| Subjects: | |
| Online Access: | http://www.mjhid.org/index.php/mjhid/article/view/2112 | 
| Tags: | Add Tag 
      No Tags, Be the first to tag this record!
   | 
Similar Items
- 
                
                    Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data        
                          
 by: Petra Belohlavkova, et al.
 Published: (2024-09-01)
- 
                
                    A rare vascular manifestation in chronic myeloid leukemia: a case report and literature review of Bier's spot development during nilotinib treatment        
                          
 by: Ahmed Alsaati, et al.
 Published: (2025-01-01)
- 
                
                    Molecular genetic and cytogenetic determinants of primary resistance or loss of the response to treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia.        
                          
 by: Kotlyarchuk K., et al.
 Published: (2015-09-01)
- 
                
                    Molecular genetic and cytogenetic determinants of primary resistance or loss of the response to treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia.        
                          
 by: K. Kotlyarchuk, et al.
 Published: (2015-09-01)
- 
                
                    Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Analysis on Behalf of the Polish Adult Leukemia Group        
                          
 by: Ugo Giordano, et al.
 Published: (2025-01-01)
 
       